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Abstract: 
Adrenal myelolipoma is an invariably benign neoplasm of the adrenal gland that is the second 
most common primary adrenal incidentaloma following adrenocortical adenomas. It is 
composed of elements of adipose tissue and extramedullary hematopoiesis. Hypotheses on 
stem cells and hormonal factors have been formulated regarding its pathogenesis that is still 
obscure. Despite its benign behaviour, adrenal myelolipoma is clinically relevant as it might 
cause significant difficulties in the differential diagnosis of adrenal tumors. We have reviewed 
420 cases reported between 1957 and 2017 on adrenal myelolipoma retrieved from PubMed 
and Scopus databases and also 20 of our case series to provide a comprehensive analysis of 
their pathology, epidemiological and clinical features. The average age for its diagnosis was 
51 years, and no gender difference was observed. The average size of tumors was 10.2 cm. 
Congenital adrenal hyperplasia was associated to 10 % of all cases analyzed, while other 
adrenal hypersecretory disorders (cortisol, aldosterone) were found in 7.5 % of cases. 
Computed tomography and magnetic resonance imaging can be reliably used for its 
differential diagnosis. If the diagnosis of an adrenal myelolipoma is unambiguous, and no 
associated symptoms or hormonal activity are established, surgical intervention is usually not 
necessary. 
Keywords: adrenal myelolipoma, congenital adrenal hyperplasia, differential diagnosis, 
management  
 
Abbreviations: ACTH: adrenocorticotropic hormone; AML: adrenal myelolipoma; CAH: 
congenital adrenal hyperplasia; EMH: extramedullary hematopoiesis 
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Introduction 
Myelolipoma is an invariably benign neoplasm of the adrenal cortex. The tumor is composed 
of fat and myeloid tissue and is listed in the group of mesenchymal and stromal tumors of the 
adrenal cortex according to the latest update of World Health Organization on endocrine 
tumors [1]. Despite its benign behavior, adrenal myelolipoma (AML) is clinically relevant as 
it might cause significant difficulties in the diagnosis of adrenal neoplasms. The number of 
case reports on adrenal myelolipomas has greatly increased in the last decades. This 
phenomenon is probably related to the more advanced and wide-spread use of abdominal 
imaging modalities [computed tomography (CT) and magnetic resonance imaging (MRI)] 
leading to the increased incidence of adrenal incidentalomas including AML.  
Adrenal myelolipomas are found in one out of 500-1250 autopsy cases [2]. However, 
it is almost impossible to assess the exact clinical prevalence of the tumor because of the high 
percentage of asymptomatic cases and its benign behavior. Following the adrenocortical 
adenoma accounting for 60-70% of adrenal incidentalomas, AML is the second most common 
primary adrenal incidentaloma representing 6-16% of adrenal incidentalomas [3–5]. 
Myelolipomas can rarely appear at other sites of the human body, as well, hence the term 
extra-adrenal myelolipoma. Among numerous locations, myelolipomas have been described 
in the mediastinum [6], spleen [7], kidney [8], bones [9], thorax [10], nasal cavity [11], 
ectopic adrenal cortex [12, 13] as well as at extradural sites [14] or in the eyes [15]. 
Biochemically, myelolipomas are mostly non-functional. 
Our aim has been to review all available case reports and other articles on adrenal 
myelolipoma in order to present a comprehensive view on this tumor. We have studied 420 
histologically verified clinical cases of adrenal myelolipoma found in reviews and case 
reports of PubMed and Scopus databases from 1957 to 2017. Moreover, we have included 20 
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of our documented, histologically verified cases. (Data of all adrenal myelolipoma cases 
included in our analysis are presented in Supplementary Table 1.) We listed only the cases 
where detailed clinical information was available and that could be clearly differentiated from 
each other and are not only parts of larger series. 
 
Pathogenesis 
Myelolipomas are composed of mature adipocytes and trilinear hematopoietic cells just as the 
properly functioning bone marrow and the extramedullary hematopoiesis (EMH) caused by 
chronic hematopoietic disorders. Extramedullary hematopoiesis is a physiologic condition 
during fetal development until the bone marrow maturates. These spots of hematopoiesis can 
take place in different organs like liver or spleen. After birth, EMH is mostly associated with 
pathological processes such as myeloproliferative disorders (e.g. myelofibrosis) or 
haemoglobinopathies (e.g. thalassemias) [16]. According to our current view, EMH and 
myelolipoma are two different entities but with nearly the same pathological appearance. Both 
differ from the bone marrow by the lack of reticular sinusoids. In the general clinical practice, 
the decision between EMH and myelolipoma is based on clinical features: EMH usually 
occurs in hematological conditions, while myelolipoma is a tumor that is accompanied by a 
healthy bone marrow [17]. Myelolipomas are encapsulated or well-demarcated lesions, and 
are composed of fat cells and have normal marrow hematopoietic elements. On the other 
hand, extramedullary hematopoiesis is not circumscribed, and fat is not its obligatory 
component [18].  
The pathogenesis of myelolipoma is obscure. It is hypothesized that the primary event 
is a metaplastic change occuring in the reticuloendothelial cells of the blood capillaries due to 
stimuli like necrosis, infection or stress [19–21]. One report described the presence of a 
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balanced translocation of (3;21)(q25;p11) in the tumor, but its pathogenic relevance is unclear 
[22]. Bishop et al. found that the majority of myelolipomas had non-random X-chromosome 
inactivation suggesting the clonal origin of these tumors [23]. Another hypothesis claims that 
adrenal myelolipoma originates from the interaction of two different kinds of progenitor cells. 
First, adipose tissue develops from mesenchymal stem cells harbored in the vessel wall of 
stromal fat of adrenal cortex under certain stimuli. When adipocytes are differentiating and 
maturing, they become inflammatory and stimulate the adrenal cortex to release factors or 
substances that recruit circulating hematopoietic progenitors to settle and differentiate [24].  
Another major group of hypotheses relates to hormonal pathways. Many decades ago, 
in experiments by Hans Selye, combined treatment of hypophysectomized rats with 
methyltestosterone and lyophilized anterior pituitary extracts lead to the transformation of the 
entire zona fasciculata and zona reticularis into a tissue having very similar characteristics to 
bone marrow [25]. These findings might correlate with the clinical observation, that some 
patients with untreated congenital adrenal hyperplasia having very high serum 
adrenocorticotropin (ACTH) levels develop myelolipoma. A case of ectopic ACTH 
overproduction due to a lung carcinoma associated with myelolipoma has been reported [26]. 
However, a Japanese group could not confirm the over-expression of ACTH receptors in the 
myelolipoma of a CAH patient that argues against ACTH to be a major causative factor [27]. 
Another hormonal overstimulation theory suggests stimulation via higher level of 
erythropoietin caused by chronic anemia [20, 28].  
It might be possible that both altered mesenchymal stem cell functioning and 
hormonal stimuli act together in the pathogenesis of myelolipoma. 
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Pathology 
Common macroscopic findings of adrenal myelolipomas include a capsule or pseudocapsule, 
yellow and red/brown cut surfaces, and hemorrhage. Capsules and the absence of a capsule 
were reported in 26% and 1% of all reported cases, respectively. However, 73% of the case 
reports did not provide any information about capsules in our statistics. Pseudocapsule is an 
outer layer that contains the compressed zona glomerulosa and zona fasciculata. On the cut 
surface, yellow color corresponds to the adipose tissue while red or brown color pertains to 
the hematopoietic tissue. Myelolipomas are round or elliptical tumors with varying diameter 
from a few millimeters up to 43 centimeters, and with an average of 10.2 centimeters 
according to our analysis. Tumors exceeding 10 cm in diameter are called giant myelolipomas 
[20]. In our analysis, 161 reported tumors belong to this category, which is 35.7% of all cases. 
However, giant myelolipomas are more likely to be reported in case reports forming the basis 
of our analysis, thus their might be a publication bias. Difference in diameter between right- 
and left-sided tumors was not observed (average right: 10.2 centimeters, average left: 10.3 
centimeters). The heaviest reported AML so far was 11400 grams [29]. The weight of the 
tumors poorly correlates - especially in the bigger ones – with the diameter because of 
intratumoral hemorrhages and the varying ratio between adipose tissue and hematopoietic 
tissue (Figure 1.). Hemorrhages on the cut surface were seen and mentioned in 19% of the 
cases. 
The characteristic microscopic appearance of myelolipoma is usually a dense adipose 
tissue, which can occasionally vary. The other constant component is trilineage hematopoietic 
tissue with the abundance of erythroid and granulocytic/lymphoid elements as well as 
megakaryocytes. Rarely, myelolipomatous foci were found in adrenocortical adenomas or 
ganglioneuroma [30, 31]. Both associated zona fasciculata and zona glomerulosa hyperplasia 
was observed in 1% of all cases each. Zona reticularis hyperplasia was seen in altogether 2 
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cases (0.5%). In 5.7% of all cases, there is concomitant adrenocortical adenoma, as well. 
Association with adrenocortical carcinoma was rarely observed (0.5%). Other findings at 
histopathological examination in association with myelolipoma were osseous metaplasia [32], 
adrenal nodular hyperplasia, calcification, black pigmented adenoma [33], and hibernoma 
[34].  
 
Clinical findings 
Based on our analysis, AML is diagnosed at the age of 51 (SD: 14.4) years on average 
(Figure 2.). There was no remarkable difference between male and female patients, with an 
average of 50.84 years and 51.02 years, respectively. The youngest patient was 1 year old at 
the diagnosis [35], while the oldest was 83 years old [36]. Former and recent reviews suggest 
that the diagnosis of myelolipoma is more likely made in people in their fifties or sixties [37, 
38]. 434 out of 440 reports included the gender of the patient. Among these 211 (48.6%) were 
female and 223 (51.4%) male, thus no gender difference can be established. In contrast, Lam 
reported a female preponderance based on two Chinese studies [39]. 
In 362 cases of 440 analyzed AMLs, the history of the diagnosis was well documented 
In Table 1., we present the leading complaints of the patients. Except for giant myelolipomas 
leading to abdominal discomfort by mass effects, it is difficult to unambiguously associate 
these symptoms with adrenal myelolipoma. 
The laterality of tumors corresponded to previous findings describing that right-sided 
myelolipomas are more frequent [1, 20, 39]. In our analysis, 260 tumors (59.2%) were on the 
right side, 111 on the left side (25.3%), while 54 tumors (12.3%) were bilateral (no data were 
available in 15 cases). The left-sided tumors of the bilateral myelolipomas are usually slightly 
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larger (average diameter 10.9 cm on the left, and 9.3 cm on the right side), however, the 
difference was not significant (p=0.25).  
 Myelolipomas are relatively slowly growing tumors. Observations of Han et al. 
showed the growths of 13 myelolipomas of 12 patients. Five tumors did not change in size, 
two tumors shrank and six grew larger. The fastest rate of growth was 5.5%/month (4.5 cm to 
5.5 cm over 4 months), while the average growing speed was 0.64% per a month [40]. In a 
most recent study, Campbell et al. found tumor growth in 11 of 69 AML cases, where follow-
up imaging by computed tomography was done at a median time interval of 3.9 years. The 
median growth per year was 0.16 cm/year (min: 0.08 cm/year, max: 0.71 cm/year), but the 
authors claimed that the growth pattern of these tumors might not be always constant or 
predictable [41]. Follow-up of larger AML cohorts would be needed to assess their growth 
rate that could form the basis for clinical recommendations. 
Spontaneous rupture of an AML may result in chronic retroperitoneal hemorrhage or 
very rarely even in hemorrhagic shock [42]. Rupture of tumor was found in 4.5% of all cases 
(20 cases). The median diameter of ruptured tumors was 120 mm. Most of the bleeding 
adrenal myelolipomas were larger than 10 cm. The smallest AML reported to bleed was 6.5 
cm large [36]. 
Associated disease was found in the majority of patients. 98 patients had hypertension 
while 41 had type 2 diabetes mellitus.  
Endocrine disorders were the most prevalent in myelolipoma patients. Among the 440 
patients analyzed, 44 patients had congenital adrenal hyperplasia (CAH) accounting for 10% 
of all cases. 35 patients had 21-hydroxylase deficiency (6 salt-wasting, 13 simple virilizing, 3 
non-classical, and 19 no further detailed). The second most common form was the 17-alpha-
hydroxylase deficiency with 5 cases. 11-beta-hydroxylase deficiency was only present in one 
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case. Among the CAH patients, bilateral myelolipomas were found in almost half of the cases 
(18 cases, 51%), 12 myelolipomas were left-sided (34%), while right-sided tumors were only 
in minority (5 cases, 14%), thus this trend is opposite to the non-CAH-associated AML, 
where right-sided is more frequent. CAH were newly diagnosed or poorly managed in 26 
cases out of 44.  
23 patients had hypercortisolism and nine had primary aldosteronism associated to 
myelolipoma, In 4 cases, androgen secretion was documented. Hypogonadism, primary 
hyperparathyroidism and pheochromocytoma were found in two cases each. Other reported 
endocrine diseases included Carney’s complex [43], polycystic ovary syndrome [44], 
papillary thyroid cancer [45] and hyper- or hypothyroidism, Multiple Endocrine Neoplasia 
syndrome type 1 [46], and Nelson syndrome [47], but these are unlikely to represent real 
associations. Complaints and symptoms of hypercortisolism, hyperaldosteronism and 
hyperandrogenism typically vanished after the myelolipoma was removed. Altogether 33 
tumors were observed that produced any kind of adrenal gland hormone apart from cases of 
CAH, which is 7.5% of all cases. Moreover, the average size of functioning tumors is smaller 
(68.5 mm) than of the non-functional lesions (104.4 mm) that is possibly related to the earlier 
diagnosis of hormone-secreting tumors. The observation of adrenal hypersecretory disorders 
associated with adrenal myelolipoma might indicate that AML is not always a tumor 
composed purely of elements of adipose and extramedullary hemopoetic tissues, but might 
even include adrenocortical parts accounting for steroid hypersecretion. Certainly, our 
analysis of case reports might result in a skewed estimate due to publication bias, and the 
actual hormonal activity of AML might be somewhat lower. 
Non-endocrine disorders were found in 56 patients. Among these 12 (2.7%) had 
thalassemia, 6 (1.3%) had renal cell cancer, and 3 had prostate cancer. Sickle cell disease, 
atrial fibrillation, breast cancer, gastric cancer and endometrial cancer were observed in two 
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cases each. The association with thalassemia is noteworthy, as extramedullary hematopoiesis 
may occur in thalassemia, again hinting at a potential common pathogenic pathway in the two 
disease entities. Detailed patient characteristics, including bibliographical data for the case 
reports studied are included in Supplementary Table 1. 
 
Imaging features 
Ultrasonography 
Myelolipoma is a benign tumor that contains adipose and hematopoietic tissue and while it 
expands it does not infiltrate the adjacent tissues. Accordingly a well-demarcated, 
hyperechoic and heterogenous mass can be seen growing out of the adrenal gland (Figure 3.). 
Calcification is often observed. The ultrasound picture of myelolipoma is diagnostically 
inadequate, and therefore further imaging by computed tomography or magnetic resonance 
imaging is necessary. 
 
Computed Tomography (CT) 
On CT scans, myelolipomas are well-circumscribed, round or elliptical, hypodense and 
heterogenous masses (Figure 4.). Attenuation values of -120 - -90 HU are characteristic of 
the adipose tissue, and the presence of fat density is useful and pivotal in diagnosing the mass 
as a myelolipoma (Figures 4a and 4b). The average attenuation values vary because the 
proportion of the fatty component is variable. Atypical radiological features like hemorrhage, 
calcification can be seen [20]. On PET-CT, FDG uptake is usually absent [48], however the 
hematopoietic elements can rarely produce an intense 
18
fluorodeoxyglucose uptake [49].  
11 
 
 
Magnetic Resonance Imaging 
On T1 and T2 weighted sequences, fat is hyperintense and well recognizable without fat 
suppression. The presence of fat can be confirmed with fat suppression. The tumors are 
almost always well-demarcated and heterogeneous. Boraschi et al. described three different 
morphologies on MRI when imaging myelolipomas (based on altogether six cases): 1) 
homogenous, hyperintense masses on T1 weighted sequences with intermediate signals on T2 
weighted images; 2) heterogenous masses with fat intensity areas and hyperintense areas on 
T2 weighted images; 3) nodules hypointense to the liver on T1 weighted sequences and after 
gadolinium administration hyperintense on T2 weighted images suggesting tumors of myeloid 
elements [50]. A similar study with similar conclusions were presented again by Musante 
with 6 patients [51].  
 
Differential diagnosis 
It is very important to differentiate between myelolipomas and other lipomatous adrenal 
tumors. These masses include adrenocortical adenoma, adrenocortical carcinoma, 
retroperitoneal liposarcoma, exophytic renal angiomyolipoma and adrenal lipoma.  
Adrenocortical adenomas are well-defined, homogenous, sharply marginated masses. 
To diagnose adrenocortical adenoma in routine clinical practice, an upper threshold value of 
10 HU was set for lipid rich adenomas that cover 70% of all ACAs. In 30% of the cases, the 
attenuation value is higher than 10 HU pertaining to lipid-poor adenomas. Adenomas are 
isointense relative to liver and hyperintense relative to spleen on T1 weighted MRI [52].  
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Adrenocortical carcinomas (ACC) are usually large, in many cases lobulated tumors, 
which often have cystic, necrotic or hemorrhagic parts. ACCs are heterogeneous with 
irregular margins, can invade adjacent structures like liver, kidney, inferior vena cava. 
Attenuation values on CT are >10 HU in most cases. Due to tumor necrosis, low attenuation 
is visible in the central area. Peripheral nodular enhancement on contrast–enhanced CT is 
typical. The tumor gives low signal on T1 weighted MRI sequence and heterogeneously high 
signal on T2 weighted sequence. 
18
FDG-PET can be considered in the differential diagnosis 
[53–55].  
Renal angiomyolipoma is the most common benign mesenchymal tumor of the kidney, 
which is composed of mature fat, blood vessels and smooth muscle cells. It is a large necrotic 
tumor, and in the majority of the cases it extends through the renal capsule. On ultrasound, a 
homogenously echodense mass can be seen. CT image gives negative attenuation values. 
When a fat-containing solid mass growing out of kidney is seen, it is with high probability an 
angiomyolipoma. On T1 weighted MRI the tumor is hyperintense relative to the renal 
parenchyma and isointense relative to fat [56, 57]. 
Retroperitoneal liposarcoma grows slowly, infiltrates the adjacent tissues and rarely 
gives metastasis. Three grades of aggressiveness are known histologically. The well-
differentiated lipogenic type is the most common form and is mostly similar to myelolipoma 
on radiological images. Contrast enhancement is visible on CT. Inhomogeneous and not well-
demarcated mass is highly similar to myelolipoma [58]. 
The differential diagnosis of adrenal lipoma is only possible by the histological 
examination of the removed tumor, as it contains no myeloid elements. Adrenal lipoma is 
extremely rare (only 24 well-documented cases in the literature), and being also a benign 
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tumor [39], its differential diagnosis from myelolipoma cannot be regarded as clinically 
relevant. 
 
Clinical management 
Due to the lack of formal guidelines regarding the management of adrenal myelolipomas, the 
decision should be made on a case-to-case basis. The majority of myelolipomas are found 
incidentally, not causing any trouble to the patient. These tumors are generally smaller than 
those producing symptoms due to mass effects. If the diagnosis of myelolipoma is 
unambiguous based on imaging, and there are no myelolipoma-related symptoms, no 
treatment is necessary. Surgical resection is the only treatment option if needed. Regarding 
adrenocortical adenomas, the European Society of Endocrinology’s latest guideline proposes 
that if an incidentaloma is homogenous, its imaging features are consistent with a benign 
adrenal mass (<10 HU) and smaller than 4 cm in diameter, no further imaging is needed [55, 
59, 60]. Myelolipomas, on the other hand, are usually larger tumors, but also slowly growing. 
Due to the lack of sufficient data, it would be difficult to determine the threshold diameter, 
above which imaging by follow-up could be proposed. Follow-up of giant myelolipomas 
(diameter>10 cm), however, may be warranted, but the frequency for follow-up is yet to be 
determined. Being larger than adrenocortical adenomas, follow-up of AMLs by 
ultrasonography might be feasible.  
The issue on the necessity of hormonal evaluation of AML is debated. In the AACE 
guideline, Zeiger et al. did not propose hormonal evaluation for obvious myelolipoma [61]. 
Similarly, Terzolo et al. propose no routine hormonal work-up for patients with AML, either 
[62]. In contrast, Shenoy et al. argued for metabolic work-up in patients with AML [20]. 
According to our data, 18.3% of all adrenal myelolipomas are associated with some kind of 
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endocrine disorder, including congenital adrenal hyperplasia (in 10 %), and others like 
primary aldosteronism, hypercortisolism or hyperandrogenism. The clinical picture should be 
considered to be the major factor in determining the necessity for hormonal work-up. 
If surgical removal is indicated because of significant growth, symptoms (e.g. 
abdominal discomfort) or hormonal activity, laparotomy or laparoscopy can be performed. 
Laparoscopic adrenalectomy is safe and effective [63]. Two approaches are applied at 
laparoscopic surgery, the transperitoneal and retroperitoneal approach. Laparoscopic 
myelolipoma removal is possible even for cases of giant myelolipoma. Chaudhary et al. 
reported a case, wherein a 15x11 cm myelolipoma was removed successfully through a 2.5 
cm incision [64]. In another report, two giant myelolipomas of 11 and 14 cm were removed 
without complication by laparoscopic approach [65]. Large tumors can be removed much 
more easily by the transperitoneal approach than by retroperitoneal approach [66]. Shen et al. 
described a retroperitoneal approach for operating large myelolipomas by a technique 
including liposuction [67]. Two reports demonstrated that if a myelolipoma ruptures, 
transcatheter arterial embolization using gelatin sponge particles can solve retroperitoneal 
bleeding from the tumor, and can delay the definitive tumor removal to an elected operation 
[68, 69].  
 
Conclusions 
Adrenal myelolipoma is an invariably benign tumor composed of adipose and extramedullary 
hematopoietic tissue elements. It is usually a large tumor most often diagnosed in the sixth 
decade of life. Due to the variable proportion of fat and hematopoietic elements, adrenal 
myelolipoma might cause sometimes severe differential diagnostic problems mostly with 
adrenocortical cancer. Detailed imaging including CT and MRI might be helpful. If its 
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diagnosis is unambiguous, and no symptoms are associated, adrenal myelolipoma mostly 
requires no surgical intervention. 
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Legends for figures: 
 
Figure 1. a. Correlation between tumor diameter and tumor weight, Pearson correlation test 
was used; b. microscopic image of an adrenal myelolipoma. 200x magnification. Courtesy of 
Dr. Katalin Borka MD PhD, 2
nd
 Department of Pathology, Semmelweis University 
 
Figure 2. The age of patients at the diagnosis of AML. 
 
Figure 3. A representative ultrasonographic image of a left-sided giant myelolipoma 
 
Figure 4. a. CT image of a right-sided giant adrenal myelolipoma; b. CT image of a bilateral 
adrenal myelolipoma with calcifications 
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Table 1. Reported leading complaints of myelolipoma patients. 
Leading complaint 
Number of patients 
with complaint 
Percentage (%) 
Abdominal discomfort/pain 60 22.5 
Hypochondrial pain 37 13.9 
Flank pain 37 13.9 
Abdominal mass 14 5.2 
Dyspepsia 13 4.9 
Nausea/vomiting 12 4.5 
Loin pain 11 4.1 
Sudden abdominal/flank pain 9 3.4 
Intermittent pain 8 3.0 
Lower extremity paresthesia, 
edema, paralysis 
8 3.0 
Epigastric pain 6 2.2 
Shortness of breath 5 1.9 
Back pain 4 1.5 
Weight loss 4 1.5 
Fever 4 1.5 
Chest pain 3 1.1 
Virilisation 1 0.4 
Dragging sensation 1 0.4 
Generalized edema 1 0.4 
Other (below 3%) 29 10.9 
Total 267 100.0 
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